

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C8A7A9C41CCEN.html>

Date: May 2020

Pages: 1353

Price: US\$ 2,500.00 (Single User License)

ID: C8A7A9C41CCEN

Abstracts

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia – Pipeline Review, H1 2020, provides an overview of the Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key

players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 5, 60, 67, 3, 8, 60, 7 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 16 and 5 molecules, respectively.

Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (Oncology).

The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Chronic Lymphocytic Leukemia (CLL) - Overview

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics
Development

Chronic Lymphocytic Leukemia (CLL) - Drug Profiles

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products

Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Therapeutics Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acepodia Biotech Inc, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acerta Pharma BV, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020 (Contd..1), H1 2020

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020 (Contd..2), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

ABL Bio Inc

ACEA Therapeutics Inc

Acepodia Biotech Inc

Acerta Pharma BV

ADC Therapeutics SA

Adlai Nortye Biopharma Co Ltd

Aeglea BioTherapeutics Inc

Agenus Inc

AI Therapeutics

Anew Oncology Inc

Apotex Inc

Apra Therapeutics AB

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Astex Pharmaceuticals Inc

AstraZeneca Plc

AVM Biotechnology LLC

Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing GD Initiative Cell Therapy Technology Co Ltd
Beijing Immunochina Medical Science & Technology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
BendaRx Corp
Bio-Path Holdings Inc
BioIntegrator Ltd
Bionomics Ltd
BioNTech SE
BioXpress Therapeutics SA
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
CARsgen Therapeutics Ltd
CASI Pharmaceuticals Inc
Catapult Therapeutics BV
Celldex Therapeutics Inc
Cellecstar Biosciences Inc
Cellular Biomedicine Group Inc
Celularity Inc
Centaurus Biopharma Co Ltd
Checkpoint Therapeutics Inc
Chengdu Brilliant Pharmaceutical Co Ltd
CrystalGenomics Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Deciphera Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
Ergon Pharmaceuticals LLC
Eternity Bioscience Inc
Eureka Therapeutics Inc
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
GeneaMed Ltd
Genentech Inc

Generium
Genmab AS
Gilead Sciences Inc
GLG Pharma SA
Grid Therapeutics LLC
Grupo Ferrer Internacional SA
Guangzhou BeBetter Medicine Technology Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Harrow Health Inc
Heidelberg Pharma AG
Helocyte Biosciences Inc
Hengenix Biotech Inc
HRAIN Biotechnology Co Ltd
Hutchison MediPharma Ltd
Hybrigenics SA
iBio Inc
IGM Biosciences Inc
Iksuda Therapeutics Ltd
Ildong Pharmaceutical Co Ltd
Immatics Biotechnologies GmbH
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
ImmunityBio Inc
Immunomedics Inc
Incuron LLC
Incyte Corp
Inflection Biosciences Ltd
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Invectys SA
IO Biotech ApS
Iovance Biotherapeutics Inc
Johnson & Johnson
Juno Therapeutics Inc
Kancera AB
Kangpu Biopharmaceuticals Ltd
Karus Therapeutics Ltd

Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
LegoChem Biosciences Inc
LFB SA
Light Chain Bioscience
Mabion SA
MEI Pharma Inc
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
MingSight Pharmaceuticals Inc
Miragen Therapeutics Inc
MorphoSys AG
Mustang Bio Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
NantKwest Inc
Nichi-Iko Pharmaceutical Co Ltd
Nordic Nanovector ASA
NovalGen Ltd
Novartis AG
Nurix Therapeutics Inc
OncoTartis Inc
Oncternal Therapeutics
Ono Pharmaceutical Co Ltd
Orano Med LLC
Panorama Research Inc
PEP-Therapy SAS
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Pharmapraxis
PIQUR Therapeutics AG
Plexxikon Inc
Precision Biosciences Inc
Promethera Biosciences SA
Qurient Co Ltd
Revitope Oncology Inc

Rhizen Pharmaceuticals SA
Sanofi
SFA Therapeutics LLC
Shanghai GeneChem Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Inc
Shanghai Yingli Pharmaceutical Co Ltd
Sian Wuhan Medical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
SpecificiT Pharma Inc
Starton Therapeutics Inc
Supratek Pharma Inc
Surface Oncology Inc
Suzhou Sinovent Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TG Therapeutics Inc
Tolero Pharmaceuticals Inc
Trillium Therapeutics Inc
United BioPharma Inc
VelosBio Inc
Verastem Inc
Viralytics Pty Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
XEME BioPharma Inc
Zhejiang DTRM Biopharma LLC
Zhejiang Teruisi Pharmaceutical Inc
ZIOPHARM Oncology Inc

I would like to order

Product name: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C8A7A9C41CCEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8A7A9C41CCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970